Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
Top Cited Papers
Open Access
- 25 November 2010
- journal article
- Published by American Society of Hematology in Blood
- Vol. 116 (22), 4422-4429
- https://doi.org/10.1182/blood-2010-03-276485
Abstract
Patients ≥ 70 years of age with acute myeloid leukemia (AML) have a poor prognosis. Recent studies suggested that intensive AML-type therapy is tolerated and may benefit most. We analyzed 446 patients ≥ 70 years of age with AML (≥ 20% blasts) treated with cytarabine-based intensive chemotherapy between 1990 and 2008 to identify risk groups for high induction (8-week) mortality. Excluding patients with favorable karyotypes, the overall complete response rate was 45%, 4-week mortality was 26%, and 8-week mortality was 36%. The median survival was 4.6 months, and the 1-year survival rate was 28%. Survival was similar among patients treated before 2000 and since 2000. A multivariate analysis of prognostic factors for 8-week mortality identified the following to be independently adverse: age ≥ 80 years, complex karyotypes, (≥ 3 abnormalities), poor performance (2-4 Eastern Cooperative Oncology Group), and elevated creatinine > 1.3 mg/dL. Patients with none (28%), 1 (40%), 2 (23%), or ≥ 3 factors (9%) had estimated 8-week mortality rates of 16%, 31%, 55%, and 71% respectively. The 8-week mortality model also predicted for differences in complete response and survival rates. In summary, the prognosis of most patients (72%) ≥ 70 years of age with AML is poor with intensive chemotherapy (8-week mortality ≥ 30%; median survival < 6 months).This publication has 46 references indexed in Scilit:
- Daunorubicin Versus Mitoxantrone Versus Idarubicin As Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10Journal of Clinical Oncology, 2009
- Anthracycline Dose Intensification in Acute Myeloid LeukemiaThe New England Journal of Medicine, 2009
- High-Dose Daunorubicin in Older Patients with Acute Myeloid LeukemiaThe New England Journal of Medicine, 2009
- Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignanciesBlood, 2009
- Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia RegistryBlood, 2009
- Trends in the Treatment of Acute Myeloid Leukaemia in the ElderlyDrugs & Aging, 2005
- High-dose chemotherapy in high-risk myelodysplastic syndromeCancer, 2001
- Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment TrialsThe New England Journal of Medicine, 1999
- Acute Myeloid LeukemiaThe New England Journal of Medicine, 1999
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994